Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs.

The patent cliff looms large. UBS analyst Michael Yee pointed to roughly "$15-20B in revenues from key drugs losing patent exclusivity" over the next three years, including blockbusters Vyndaquel, ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...

In its upcoming report, Pfizer (PFE) is predicted by Wall Street analysts to post quarterly earnings of $0.57 per share, reflecting a decline of 9.5% compared to the same period last year. Revenues ...

On Thursday, Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) announced results from the Phase 3 PATINA trial. The trial demonstrated that the addition of IBRANCE (palbociclib) to ...

Pfizer remains a 'Buy' at current low valuation multiples, but faces significant headwinds from an impending patent cliff through 2030. Pfizer's top-line growth is challenged by steep declines in ...